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ABSTRACT
Objectives Pressures on healthcare systems due to 
COVID-19 has impacted patients without COVID-19 with 
surgery disproportionally affected. This study aims to 
understand the impact on the initial management of 
patients with brain tumours by measuring changes to 
normal multidisciplinary team (MDT) decision making.
Design A prospective survey performed in UK 
neurosurgical units performed from 23 March 2020 until 
24 April 2020.
Setting Regional neurosurgical units outside London (as 
the pandemic was more advanced at time of study).
Participants Representatives from all units were invited 
to collect data on new patients discussed at their MDT 
meetings during the study period. Each unit decided if 
management decision for each patient had changed due 
to COVID-19.
Primary and secondary outcome measures Primary 
outcome measures included number of patients where 
the decision to undergo surgery changed compared 
with standard management usually offered by that 
MDT. Secondary outcome measures included changes 
in surgical extent, numbers referred to MDT, number of 
patients denied surgery not receiving any treatment and 
reasons for any variation across the UK.
Results 18 units (75%) provided information from 80 
MDT meetings that discussed 1221 patients. 10.7% of 
patients had their management changed—the majority 
(68%) did not undergo surgery and more than half of this 
group not undergoing surgery had no active treatment. 
There was marked variation across the UK (0%–28% 
change in management). Units that did not change 
management could maintain capacity with dedicated 
oncology lists. Low volume units were less affected.
Conclusion COVID-19 has had an impact on patients 
requiring surgery for malignant brain tumours, with 
patients receiving different treatments—most commonly 
not receiving surgery or any treatment at all. The variations 
show dedicated cancer operating lists may mitigate these 
pressures.
Study registration This study was registered with 
the Royal College of Surgeons of England’s COVID-19 
Research Group (https://www. rcseng. ac. uk/ coronavirus/ 
rcs- covid- research- group/).
BACKGROUND
The COVID-19 pandemic has caused an 
unprecedented threat to healthcare delivery 
worldwide. Hospitals dealing with large 
numbers of patients requiring critical care 
have redeployed staff and converted oper-
ating rooms into intensive care units to cope 
with infected patients. This has had a marked 
impact on services and patient care for 
patients without COVID-19. Surgery has been 
disproportionately affected and requests 
to maintain urgent cancer surgery requires 
careful patient triage.1 2
Strengths and limitations of this study
 ► This is a national survey that covers 75% of the UK 
units outside London providing a view of the impact 
COVID-19 had on the management of patients with 
brain tumours across the UK.
 ► Our data are based on 1221 patients.
 ► Data collection occurs 2 weeks before and 2 weeks 
after the peak of COVID-19 infections.
 ► We have not collected patient- level data so can’t as-
sess what happens to individual patients.
 ► We have only looked at surgical management and 
do not have data on oncology treatment.
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In the UK adult brain tumours are managed across 30 
regional neurosurgical centres, 24 of these are outside 
London. All new brain diagnoses are discussed in a 
multidisciplinary team (MDT) meeting that decides 
the optimal treatment for each patient. Each MDT will 
review a range of tumours from non- malignant or slow- 
growing (low- grade) tumours whose initial treatment 
could be safely deferred, to the malignant tumours that 
are characterised by rapid growth and patient deterio-
ration without treatment in a matter of weeks. Surgery 
is the main initial treatment for most patients—it can 
cure non- malignant tumours, remove the bulk of malig-
nant tumours and is the only way of providing tumour 
tissue for pathological and molecular diagnosis to 
guide further treatment. Although surgery is not cura-
tive in malignant tumours, it does prolong good quality 
survival. National guidelines recommended that surgery 
for malignant tumours should continue during the 
COVID-19 pandemic providing adjuvant oncology treat-
ment is available.3 The role of the MDT is critical to good 
patient management.
We undertook a national survey to evaluate the impact 
of COVID-19 on neurosurgical oncology services and 
to explore differences and variations in MDT decisions 
compared with the pre- COVID-19 era to investigate if 
patients were denied access to surgery.
METHODS
Project leads from each of the UK neurosurgical units 
were identified to prospectively collect information from 
their weekly neuro- oncology MDT between 23 March 
and 20 April 2020. London units were excluded as the 
pandemic peak was more advanced at the time of this 
study.
The primary outcome measure in this study is the 
change in MDT decision making. This was determined 
by each MDT. At each MDT meeting, the project lead 
would review the decisions made for every patient 
with the rest of the team and decide whether this deci-
sion had differed from their normal practice due to 
COVID-19.
At each MDT meeting, the following data were 
recorded:
 ► Total number of new patients discussed.
 ► Number of patients where the MDT felt their initial/
surgical treatment was different from their standard 
management due to COVID-19.
 ► Number of patients who did not receive surgery or 
whose surgical treatment intent was changed (eg, 
biopsy rather than resection).
 – From the group that did not undergo surgery, the 
number of the patients who did not receive any ac-
tive treatment (ie, supportive care only).
 ► Number of patients who had undergone surgery for 
a malignant tumour (defined as high- grade glioma, 
metastatic tumour or other,rarer malignant tumour).
Variations in decision making
Data were compared with a baseline MDT workload from 
the 4 weeks of February (3–28 February 2020) to provide 
information on the impact of COVID-19. To explore the 
variations in MDT decision making, funnel plots for the 
proportion of cases discussed where management was 
altered were generated using Microsoft Excel, with 95% 
and 99.8% control limits calculated using the Wilson 
Score method for binomially distributed variates.4 Project 
leads were invited to comment with free text on how 
their unit responded to COVID-19. Using this free text, 
we developed three groups that arranged units based on 
commonly expressed themes of how they managed to 
mitigate the challenges of COVID-19.
Statistical analysis
Statistical analysis was performed using IBM SPSS V.26. 
All variables were assessed for normality using a 1- sample 
Kolmogorov- Smirnov test. Changes in the weekly mean 
number of new patients discussed at MDT meetings 
and operations for malignant tumours was assessed 
using paired t- test. Correlation of these variables with 
changes of MDT decision rates was made using a Pearson 
correlation.
Patient and public involvement
Patients/the public were not involved in the concept or 
design of this study as this came about from concerns 
among professionals at the services they were providing 
patients. A patient/public representative was appointed 
to the study group during the project set up to comment 
on the results.
RESULTS
Eighteen of the 24 eligible neurosurgical units (75%) 
participated in the study. A total of 1221 new patients 
were included from 80 MDT meetings. In all units, the 
functioning of the MDT changed with eight units (33%) 
moving to fully video conferencing, all of the other units 
would limit attendance to a smaller number of senior 
representatives of different specialities (eg, neurosurgery, 
oncology, radiology, etc). Four units (17%) reduced the 
duration of the meeting.
Comparing activity to baseline, there was a significant 
reduction in the number of new patients discussed from 
a mean weekly baseline table 1. In total, 131 patients 
(10.7%) had a change in their initial management due 
to COVID-19. Of these, 15 (11.5%) had a change of 
surgical intent, and 90 (68%) had no surgery at all. Forty- 
seven patients (52% of those decided for no surgery) 
were decided for best supportive care. Information from 
project leads suggest the majority of these patients were 
elderly and had poor performance status. Other reasons 
for not operating were patients with low- grade gliomas or 
meningiomas whose surgery was deferred until after the 
critical phase of the pandemic.
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The change in initial management varied between 
centres and ranged from 0% to 28%. This did not 
correlate with either the change in the number of 
weekly operations (R=−0.03; p=0.91) nor the number 
of patients discussed at an MDT meeting (R=−0.29; 
p=0.29). The funnel plot identified three groups of 
units (figure 1). Group A was smaller units with low 
numbers of new patients with brain tumour (mean=7.4, 
95% CI 4.1 to 10.6) and low rates of management 
changes. Project leads commented that COVID-19 had 
less impact on their units or were able to cope with the 
numbers of referrals. The group included a unit whose 
numbers decreased from 28.5 to 13.6 per week (52% 
reduction). Group B was larger units (mean weekly new 
patients=34.1, 95% CI 20.9 to 47.2) that allocated dedi-
cated oncology lists. This was achieved by a variety of 
methods—implementing daily oncology lists, managing 
patients as emergencies or using the private hospital 
sector to provide space to treat brain tumour patients. 
Group C was the group with the largest change in 
management. A common theme for this group was the 
lack of dedicated oncology lists—patients with malig-
nant tumours competing for surgical theatre operating 
time with other urgent surgical cases.
Patient/public interpretation of results
The results were examined by the study group’s patient/
public representative (HB). They commented that “when 
you're diagnosed with a brain tumour, your whole life is 
not only upended but put on hold. At this point, patients 
and their families need certainty. To be denied surgery—
the first- line treatment—doesn't bear thinking about. 
This impacts on the whole of the patient pathway, as 
without biopsies and resections, nobody really knows what 
you are treating, or how much tumour you are treating. 
It undermines the whole of the personalised medicine 
agenda and this cohort of patients will be living with the 
consequences, but probably not for as long as they would 
have been if they had had surgery. The short- sighted deci-
sion to bypass brain tumour surgery is undoubtedly short-
ening patients’ lives.”
Table 1 Changes in workload between baseline and COVID-19 period. Malignant tumours refer to high- grade gliomas, 
metastases and other rarer malignant tumours
Baseline During study period Significance Difference
Number of new patients 21.2 (95% CI 14.0 to 
28.3)
15.3 (95% CI 10.0 to 
20.6)
t=−4.26, p=0.0005 ↓27%
Number of operations for malignant 
tumours
4.1 (95% CI 3.2 to 5.0) 3.0 (95% CI 2.0 to 4.1) t=−2.76, p=0.01 ↓26%
Figure 1 Funnel plot showing variation in number of patients whose management was changed due to COVID-19 versus the 
number of patients discussed in MDTs over the study period. SD curves have been included. we have broken the data into three 
groups with different responses to the pandemic.
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DISCUSSION
This national study has shown the impact COVID-19 has 
had on MDT decision making for malignant (gliomas 
and metastases) brain tumour patients. In total, 10.7% of 
patients had their initial management changed, of which 
the majority (68%) did not undergo surgery. Over half of 
these patients had palliative care only. Surgery is the first- 
line treatment in malignant brain tumours and extent 
of resection is the only modifiable prognostic factor.5 
Patients with glioblastomas, the most common malig-
nant primary tumour, have a very limited survival without 
treatment,6 and surgical resection improves the efficacy 
of adjuvant therapies and quality of life.7
Like other cancers, COVID-19 has impacted on refer-
rals.8 We found a 27% reduction in a number of patients 
discussed and operations performed for malignant 
tumours (26% reduction) (cf. table 1). Initial symptoms 
of brain tumours are frequently non- specific, and patients 
often present when they decompensate.9 10 The reduction 
in new tumour referrals during this study may result in 
patients presenting later and with more extensive disease.
An interesting finding was the variation between units. 
Group analysis identified trends in units that successfully 
reduced the impact of COVID-19 on MDT management. 
Strategies to ensure that dedicated cancer lists continued 
were helpful in larger units. It is clear that where cancer 
patients were scheduled on operating lists with other 
urgent cases, more substantial MDT management 
changes were needed to cope. Our findings complement 
other studies that have shown that the use of the private 
sector during this COVID-19 pandemic results in less 
disruption to services.11
The study does have limitations, principally in the 
design. The purpose was to provide a prospective, rapid 
‘snapshot’ of changes of MDT decision making during 
the peak of the pandemic using high- level data. As such, 
we did not include the detail from individual patient 
data that would perhaps allow a better explanation of 
individual variation between units. Instead, our project 
leads, all busy clinicians dealing with the impact of the 
peak of the pandemic, were able to obtain data on patient 
numbers. Although the study may lack some scientific 
rigour, it nevertheless provides a narrative of the real- 
world experiences seen by neurosurgical units during the 
height of the pandemic in the UK. Although this survey 
covered 70% of units, not all geographical areas have 
been included (eg, South West and London). We have 
not been able to include the COVID-19 infection rate 
across the country into our analysis since each neurosur-
gery unit serves a large geographical area. The dates of 
our survey, however, correspond to the peak in cases for 
every geographical region.
Our primary outcome measure was, by its nature, prag-
matic. This introduces some subjectivity between units 
as to what they defined as a change in management. As 
most of these changes involved no surgery or a change in 
surgical intent, we believe project leads reported signif-
icant changes in management that this study sought to 
explore. Our study only analysed changes in surgical 
treatment, but we know there are also changes in adju-
vant therapy, such as radiation dose and chemotherapy 
regimes. It was difficult to quantify these changes in our 
study since patients are often treated in oncology centres 
that are separate from the neurosurgery centres. The 
main focus of our study was to look at the MDT decision 
making where decisions about adjuvant therapy were 
made to influence surgery as national guidelines recom-
mend surgery for patients with malignant tumours only 
where adjuvant therapy was available.
In conclusion, COVID-19 has had an impact on patients 
requiring surgery for malignant brain tumours—with 
10.7% having a change of management due to COVID-19, 
most commonly by not having surgery and many having 
no active treatment at all. The variation of changes in 
decision making shows that dedicated cancer operating 
lists may help to mitigate the pressures of COVID-19.
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